This is a 12.5-month, single-center, open label, pilot study. Transcranial magnetic
stimulation (TMS) is well accepted in the treatment of major depressive disorder …

Background: Major depressive disorder (MDD) is the leading cause of disability worldwide
and approximately 50% of MDD patients meet criteria for treatment-resistant depression …

Objective: Depression is the leading cause of disability worldwide, and half of patients with
depression have treatment-resistant depression. Intermittent theta-burst stimulation (iTBS) is …

Background Developments regarding technical aspects of repetitive Transcranial Magnetic
Stimulation (rTMS) have been linked to better results in medication-resistant depression …

Background: Optimized Transcranial magnetic stimulation (TMS) protocols for major
depressive disorder (MDD) are needed to improve patient convenience and access. The …

Transcranial magnetic stimulation (TMS) is an effective FDA-approved treatment for
treatment-resistant major depressive disorder (MDD)[1, 2]. The most common TMS protocol …

Background: Depression is the leading cause of disability worldwide, affecting 322 million
people, half of whom have treatment-resistant depression. Intermittent theta-burst stimulation …

Objective: New antidepressant treatments are needed that are effective, rapid acting, safe,
and tolerable. Intermittent theta-burst stimulation (iTBS) is a noninvasive brain stimulation …

Accelerated TMS is an emerging application of Transcranial Magnetic Stimulation (TMS)
aimed to reduce treatment length and improve response time. Extant literature generally …

Background Transcranial magnetic stimulation (TMS) is an effective treatment for major
depressive disorder (MDD). The rest time between pulse trains is the inter-train interval (ITI) …